Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05005403
Title Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors AbbVie

head and neck squamous cell carcinoma

lung non-small cell carcinoma


ABBV-181 + ABBV-514

ABBV-514 + Pembrolizumab


Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST